Relative to the model + IL-23 group, XTS administered at doses of 1, 2, and 4 mg/kg could dose-dependently inhibit the synovial inflammatory hyperplasia and inflammatory cell infiltration in AIA rats with IL-23 overexpression (P < 0.01), and prevent joint space narrowing, suggesting that XTS has a significant anti-RA effect. Here, IL23A is linked to rheumatoid arthritis.